US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Champion Industries, Inc.

0.0200

0.0000

Volume:- -

Turnover:- -

Market Cap:1.12K

PE:0.00

High:0.0200

Open:0.0200

Low:0.0200

Close:0.0200

52wk High:0.0200

52wk Low:0.0001

Shares:55.86K

Float Shares:- -

Volume Ratio:0.08

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-23.0334

EPS(LYR):-23.0334

ROE:-49.45%

ROA:-1.87%

PB:0.00

PE(LYR):0.00

Loading ...

Overview Company News Filings

Sanofi Wins Positive EU CHMP Opinion for Rezurock in Chronic Graft-Versus-Host Disease

Neuren's Regulatory Hurdles for Trofinetide May Push Back EU Royalties, Says Jefferies

MT Newswires Live

Protalix BioTherapeutics Shares Up After CHMP Issued Positive Opinion on New Dosing Regimen for Fabry Disease Treatment

Incyte CHMP Win For Zynyz Adds Weight To Oncology Diversification Story

Simply Wall St.

Sanofi’s Rezurock recommended for EU approval by the CHMP

Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

Why Is Theriva Biologics Stock Gaining Monday?

Benzinga_recent_news

Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy

How WINREVAIR’s Expanded CHMP-Backed PAH Indication At Merck (MRK) Has Changed Its Investment Story

Simply Wall St.

European Regulator Backs Approval Of Novo Nordisk High-Dose Wegovy

The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®

Press Release: Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update

Biogen Gets CHMP Backing for Higher-Dose Spinraza

High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy

Incyte announces CHMP opinion recommending approval of Minjuvi combination

Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results

Anavex Faces CHMP Setback for Alzheimer’s Drug

Ionis Pharmaceuticals announces CHMP opinion recommending Dawnzera approval

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CHMP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CHMP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CHMP\",,,,,undefined,":{"symbol":"CHMP","market":"US","secType":"STK","nameCN":"Champion Industries, Inc.","latestPrice":0.02,"timestamp":1770411600000,"preClose":0.02,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":0,"shares":55857,"eps":-23.033406,"marketStatus":"Market Closed","change":0,"latestTime":"02-06 16:00:00 EST Delay","open":0.02,"high":0.02,"low":0.02,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-23.033406,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"EXPERT","adjPreClose":0.02,"volumeRatio":0.0817439248936818},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CHMP\",,,,,undefined,":{"symbol":"CHMP","floatShares":0,"roa":"-1.87%","roe":"-49.45%","lyrEps":-23.033406,"volumeRatio":0.0817439248936818,"shares":55857,"dividePrice":0,"high":0.02,"amplitude":0,"preClose":0.02,"low":0.02,"week52Low":0.0001,"pbRate":"0.00","psRate":"0.00","week52High":0.02,"institutionHeld":0,"latestPrice":0.02,"eps":-23.033406,"divideRate":0,"volume":0,"delay":15,"ttmEps":-23.033406,"open":0.02,"prevYearClose":0.02,"prevWeekClose":0.02,"prevMonthClose":0.02,"prevQuarterClose":0.02,"fiveDayClose":0.02,"twentyDayClose":0.02,"sixtyDayClose":0.0001},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CHMP\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CHMP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CHMP\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CHMP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609597957","title":"Sanofi Wins Positive EU CHMP Opinion for Rezurock in Chronic Graft-Versus-Host Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2609597957","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609597957?lang=en_us&edition=fundamental","pubTime":"2026-02-06 23:29","pubTimestamp":1770391748,"startTime":"0","endTime":"0","summary":"Sanofi ( ($SNY) ) has shared an announcement. On January 30, 2026, Sanofi announced that the European Medicines Agency’s Committee for Medicinal Pr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sanofi-wins-positive-eu-chmp-opinion-for-rezurock-in-chronic-graft-versus-host-disease?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/sanofi-wins-positive-eu-chmp-opinion-for-rezurock-in-chronic-graft-versus-host-disease?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SNYNF","BK4087","CHMP","BK4156","BK4181","BK4585","BK4007","HST","BK4588","BK4218"],"gpt_icon":0},{"id":"2609384536","title":"Neuren's Regulatory Hurdles for Trofinetide May Push Back EU Royalties, Says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2609384536","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609384536?lang=en_us&edition=fundamental","pubTime":"2026-02-06 08:13","pubTimestamp":1770336816,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  facing regulatory uncertainty in the European Union  for its investigational drug trofinetide to treat Rett syndrome may delay royalties from sales in the region, Jefferies said in a note on Thursday.The European Medicines Agency  Committee for Medicinal Products for Human Use  gave a negative trend vote this week on the drug candidate's market authorization application, possibly due to concerns about the effect size in the confirmatory trial.Jefferies said the negative trend vote is an early indication that the regulatory authority might issue a negative opinion on the application at the final vote.The investment firm now expects royalties from EU sales of trofinetide to kick in the fourth quarter of fiscal 2026, and not second quarter.Meanwhile, it projects Neuren's experimental drug NNZ-2591 for treating Pitt-Hopkins Syndrome, a rare neurodevelopmental disorder, will receive reimbursement approval in the US in fiscal 2029.Jefferies lowered the company's fisca","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7129","NEU.AU","BK4156","BK7508","EMA","BK4081","BK7096","EMA.AU","CHMP","BK4087"],"gpt_icon":0},{"id":"2608893279","title":"Protalix BioTherapeutics Shares Up After CHMP Issued Positive Opinion on New Dosing Regimen for Fabry Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2608893279","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608893279?lang=en_us&edition=fundamental","pubTime":"2026-02-03 00:00","pubTimestamp":1770048000,"startTime":"0","endTime":"0","summary":"Shares of Protalix BioTherapeutics jumped after the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion on a new dosing regimen of its Fabry disease treatment.The stock rose 7.9% to $2.53 in Monday morning trading. The shares have increased 3% in the past year.The biopharmaceutical company focused on rare diseases said Monday that the committee gave a positive opinion of a new dosing regimen of 2 mg per kilogram every four weeks for Protalix's Elfabrio drug.The opinion will be reviewed by the European Commission with a decision anticipated by March. If approved, Elfabrio will be available in two doses, including the already approved regimen of 1 mg per kilogram every two weeks, to patients in the European Union.Protalix, and its collaborator Chiesi Global's rare diseases unit, said the new regimen could reduce the burden to eligible patients and their families by alleviating the current requirement to visit infusion centers every two wee","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PLX","BK4087","CHMP"],"gpt_icon":0},{"id":"2608883140","title":"Incyte CHMP Win For Zynyz Adds Weight To Oncology Diversification Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2608883140","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608883140?lang=en_us&edition=fundamental","pubTime":"2026-02-01 21:25","pubTimestamp":1769952329,"startTime":"0","endTime":"0","summary":"Incyte (NasdaqGS:INCY) received a positive opinion from the European Medicines Agency's CHMP for Zynyz (retifanlimab) with chemotherapy as a first-line treatment for advanced squamous cell carcinoma of the anal canal.\nThe opinion is based on Phase 3 data showing improved outcomes without new safety signals in this patient group.\nThe CHMP decision is an important step in the EU regulatory process and could support broader availability of Zynyz for eligible patients.\n\nFor you as an investor...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-incy/incyte/news/incyte-chmp-win-for-zynyz-adds-weight-to-oncology-diversific","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-incy/incyte/news/incyte-chmp-win-for-zynyz-adds-weight-to-oncology-diversific","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4532","BK4087","BK4139","CHMP","BK4550","INCY","BK4588","BK4585"],"gpt_icon":0},{"id":"2607101020","title":"Sanofi’s Rezurock recommended for EU approval by the CHMP","url":"https://stock-news.laohu8.com/highlight/detail?id=2607101020","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607101020?lang=en_us&edition=fundamental","pubTime":"2026-01-30 20:15","pubTimestamp":1769775354,"startTime":"0","endTime":"0","summary":"The European Medicines Agency’s Committee for Medicinal Products for Human Use, CHMP, has adopted a positive opinion recommending the conditional m...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sanofis-rezurock-recommended-for-eu-approval-by-the-chmp-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sanofis-rezurock-recommended-for-eu-approval-by-the-chmp-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CHMP","BK4087","SNYNF","BK4156","BK4007"],"gpt_icon":0},{"id":"2602514796","title":"Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2602514796","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602514796?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219200,"startTime":"0","endTime":"0","summary":"Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE (pegcetacoplan injection) total injection demand grew 17% year-over-year; regulatory submission for prefilled syringe plann","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/12/3216691/0/en/Apellis-Highlights-Commercial-Execution-and-Strategic-Priorities-at-the-44th-Annual-J-P-Morgan-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1074936037.SGD","CHMP","BK4585","LU0106831901.USD","IND","LABU","LU0314104364.USD","LU0225283273.USD","LU0158827781.USD","LU2357305700.SGD","LU0106261372.USD","LU1244550494.USD","LU2347655156.SGD","BK4081","LU2089284900.SGD","BK4137","LU2023251221.USD","LU2133065610.SGD","BK4534","LU0158827948.USD","HCSG","LU0795875169.SGD","EMA","LU1989772840.SGD","LU0128526141.USD","LU0557290698.USD","LU0882574139.USD","LU1732800096.USD","LU1791710400.SGD","LU1720051017.SGD","XLV","LU2028103732.USD","LU1720051108.HKD","XBI","LU0528227936.USD","LU1162221912.USD","BK4516","LU1363072403.SGD","LU0029874061.USD","LU2271345857.HKD","LU0098860793.USD","BK4588","FSGS","LU0234570918.USD","LU0795875086.SGD","LU1732799900.SGD","LU2111349929.HKD","LU0971096721.USD","IE00BZ1G4Q59.USD","BK4087"],"gpt_icon":0},{"id":"2595734835","title":"Why Is Theriva Biologics Stock Gaining Monday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2595734835","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595734835?lang=en_us&edition=fundamental","pubTime":"2025-12-30 00:41","pubTimestamp":1767026460,"startTime":"0","endTime":"0","summary":"Theriva Biologics stock rose on Monday as it received positive Scientific Advice from CHMP for a Phase 3 trial of VCN-01 for PDAC treatment.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/29/Tumor-Microenvironment-Concept-With-Canc.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/29/Tumor-Microenvironment-Concept-With-Canc.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/12/49613988/why-is-theriva-biologics-stock-gaining-monday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/12/49613988/why-is-theriva-biologics-stock-gaining-monday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4605","LU1854104046.USD","LU1720051017.SGD","EMA","TOVX","CHMP","LU1861215975.USD","BK4215","IE00BD6J9T35.USD","IE00BZ199S13.USD","IE00BFMHRM44.USD","LU0124384867.USD","BK4585","LU2298322129.HKD","LU1548497426.USD","LU1978683503.SGD","LU2357305700.SGD","LU1861219969.SGD","LU1720051108.HKD","BK4141","LU1861214812.USD","BK4139","LU2360107325.USD","LU0724618433.USD","MAA","ON","BK4588","LU0348723411.USD","BK4512","LU1854103824.USD","BK4087","BK4081","LU1861220033.SGD"],"gpt_icon":0},{"id":"2595807267","title":"Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2595807267","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595807267?lang=en_us&edition=fundamental","pubTime":"2025-12-29 21:00","pubTimestamp":1767013200,"startTime":"0","endTime":"0","summary":"-EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of metastatic PDAC, including sample size","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/29/3210890/0/en/Theriva-Biologics-Announces-Positive-Scientific-Advice-from-the-European-Medicines-Agency-EMA-on-the-Design-of-a-Phase-3-Trial-of-VCN-01-in-Metastatic-Pancreatic-Ductal-Adenocarcin.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","CHMP","BK4585","MAA","MDCO","BK4081","EMA","BK4087","BK4215"],"gpt_icon":0},{"id":"2592997151","title":"Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China  for Patients with Obstructive Hypertrophic Cardiomyopathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2592997151","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592997151?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:30","pubTimestamp":1765974600,"startTime":"0","endTime":"0","summary":"Approval Triggers Milestone Payment of $7.5 Million from Sanofi;Cytokinetics Eligible to Receive Additional Milestone Payments and Royalties on Net Sales in Greater China SOUTH SAN FRANCISCO, Calif., ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/17/3206907/35409/en/Cytokinetics-Announces-NMPA-Approval-of-MYQORZO-aficamten-in-China-for-Patients-with-Obstructive-Hypertrophic-Cardiomyopathy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4087","CYTK","BK4531","BK4505","BK4156","HCM","BK4588","BK4585","BK4007","BK4139","CHMP"],"gpt_icon":0},{"id":"2591922662","title":"How WINREVAIR’s Expanded CHMP-Backed PAH Indication At Merck (MRK) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2591922662","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591922662?lang=en_us&edition=fundamental","pubTime":"2025-12-15 04:19","pubTimestamp":1765743562,"startTime":"0","endTime":"0","summary":"Merck recently reported that the European Medicines Agency’s CHMP has recommended expanding WINREVAIR’s pulmonary arterial hypertension indication in Europe to include higher-risk WHO Functional Class II–IV adults, following strong Phase 3 ZENITH data on morbidity and mortality outcomes.\nThis regulatory momentum strengthens WINREVAIR’s position as a differentiated activin signaling inhibitor in a serious disease area, potentially broadening its role as one of Merck’s key growth drivers...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/288502-main-header/1756255043815","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/288502-main-header/1756255043815"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-mrk/merck/news/how-winrevairs-expanded-chmp-backed-pah-indication-at-merck","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-mrk/merck/news/how-winrevairs-expanded-chmp-backed-pah-indication-at-merck","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MRK","LU1057294990.SGD","LU0130517989.USD","LU1162221912.USD","LU1023059063.AUD","SG9999001176.SGD","LU1983299246.USD","SG9999015358.SGD","BK4588","LU0106261372.USD","SG9999014542.SGD","LU1066051225.USD","LU2023250843.SGD","LU2361044949.HKD","LU1934455277.USD","LU1934455194.USD","LU0985320562.USD","LU0234572021.USD","LU1941712348.USD","LU0980610538.SGD","SGXZ57979304.SGD","LU2089984988.USD","IE00BJJMRZ35.SGD","LU1989772923.USD","SG9999013999.USD","LU0965509010.AUD","LU0070302665.USD","LU2324357040.USD","LU1934455863.HKD","BK4559","LU1929549753.HKD","LU1699723380.USD","LU1291159041.SGD","SG9999014567.USD","LU0006306889.USD","LU1093756168.USD","LU2360032135.SGD","BK4550","LU0122379950.USD","LU0058720904.USD","BK4087","SG9999002224.SGD","LU0965508806.USD","BK4534","LU1093756325.SGD","SG9999014559.SGD","LU0477156953.USD","BK4533","CHMP","LU0320765489.SGD"],"gpt_icon":0},{"id":"2591384686","title":"European Regulator Backs Approval Of Novo Nordisk High-Dose Wegovy","url":"https://stock-news.laohu8.com/highlight/detail?id=2591384686","media":"Benzinga","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591384686?lang=en_us&edition=fundamental","pubTime":"2025-12-13 02:55","pubTimestamp":1765565700,"startTime":"0","endTime":"0","summary":"On Friday, the European Medicines Agency's  Committee for Medicinal Products for Human Use  issued a positive opinion for Novo Nordisk A/S’  higher dose of Wegovy .Also Read: FDA Weighs Rapid Review For Eli Lilly Obesity Pill As Novo Nordisk Nears Launch. The new dose of Wegovy has demonstrated an average weight loss of 20.7% at 72 weeks in people with obesity who do not have diabetes.These substantial weight loss results complement the already established health benefits of Wegovy in obesity-related complications, including a significant reduction in the risk of cardiovascular events such as heart attack and stroke, and a reduction in pain from knee osteoarthritis.In people with obesity and without diabetes, one in three participants treated with Wegovy achieved 25% or more weight loss at 72 weeks, with a safety and tolerability profile consistent with the approved Wegovy 2.4 mg semaglutide dose.Data showed that the majority (84%) of the weight lost with Wegovy came from fat mass loss","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/12/Siegen--North-Rhine-Westphalia---Germany.jpeg?optimize=medium&dpr=2&auto=webp&width=630","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/12/Siegen--North-Rhine-Westphalia---Germany.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/25/12/49371241/european-regulator-backs-approval-of-novo-nordisk-high-dose-wegovy","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/12/49371241/european-regulator-backs-approval-of-novo-nordisk-high-dose-wegovy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4532","BK4087","LU0154236417.USD","BK4081","EMA","NVO","LU1093756325.SGD","IE00BKVL7J92.USD","LU1093756168.USD","IE00BZ1G4Q59.USD","BK4599","BK4588","BK4585","BK4007","CHMP"],"gpt_icon":1},{"id":"2588276470","title":"The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN","url":"https://stock-news.laohu8.com/highlight/detail?id=2588276470","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588276470?lang=en_us&edition=fundamental","pubTime":"2025-12-04 06:05","pubTimestamp":1764799500,"startTime":"0","endTime":"0","summary":"Robust and clinically meaningful benefits across all three key markers of disease – 68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 depositsConsistent r","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/03/3199410/0/en/The-New-England-Journal-of-Medicine-Publishes-Positive-Phase-3-VALIANT-Results-of-EMPAVELI-pegcetacoplan-for-C3G-and-Primary-IC-MPGN.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHMP","EMA","BK4081","BK4087"],"gpt_icon":0},{"id":"2586755564","title":"Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®","url":"https://stock-news.laohu8.com/highlight/detail?id=2586755564","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586755564?lang=en_us&edition=fundamental","pubTime":"2025-11-25 21:10","pubTimestamp":1764076200,"startTime":"0","endTime":"0","summary":"Following the positive opinions of the Committee for Medicinal Products for Human Use (CHMP), the European Commission has granted marketing authorizations for Teva’s biosimilars PONLIMSI and DEGEVMA e","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/25/3194303/0/en/Teva-receives-European-Commission-approvals-for-PONLIMSI-denosumab-Biosimilar-to-Prolia-and-DEGEVMA-denosumab-Biosimilar-to-Xgeva.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHMP","EC","BK4201","BK4087"],"gpt_icon":0},{"id":"2586647852","title":"Press Release: Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2586647852","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586647852?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:30","pubTimestamp":1764073800,"startTime":"0","endTime":"0","summary":"Company to host a webcast today at 8:30 a.m. Eastern Time. NEW YORK, Nov. 25, 2025  -- Anavex Life Sciences Corp.  , a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system  disorders, today reported financial results for its fourth quarter of fiscal 2025.\"There are currently an estimated 7.2 million people living with Alzheimer's disease in the U.S. and 7 million in Europe, respectively. We continue to be focused on orally, targeted upstream medicines, particularly in the context of early Alzheimer's disease,\" said Christopher U. Missling, PhD, President and CEO of Anavex. \"Our clinical pipeline positions Anavex to address critical unmet needs in neurodegenerative and neurodevelopmental disorders with convenient and scalable therapeutic options. Oral blarcamesine demonstrated cont","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4087","MAA","BK4139","BK4588","BK4135","BK4215","CNS","EMA","R","BK4022","BK4081","CHMP","AVXL","BK4585"],"gpt_icon":0},{"id":"2584864704","title":"Biogen Gets CHMP Backing for Higher-Dose Spinraza","url":"https://stock-news.laohu8.com/highlight/detail?id=2584864704","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584864704?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:40","pubTimestamp":1763379600,"startTime":"0","endTime":"0","summary":"Biogen said a key European regulatory committee has recommended approval of a high-dose regimen of its Spinraza drug for the neuromuscular disease spinal muscular atrophy, or SMA.Biogen on Monday said the positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use covers the high-dose regimen of Spinraza for the treatment of 5q SMA, which represents about 95% of all SMA cases.The European Commission, which generally follows CHMP's advice, will now review the recommendation, with a decision expected in January, the Cambridge, Mass., biotechnology company said.The U.S. Food and Drug Administration is reviewing Biogen's application for the high-dose regimen, with a decision due by early April.Spinal muscular atrophy is a rare genetic disease characterized by a loss of motor neurons in the spinal cord and lower brain stem, resulting in severe, progressive muscle atrophy and weakness.Spinraza generated worldwide sales of $1.19 billion for the first n","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","IONS","LU0320765992.SGD","LU0889565916.HKD","BK4532","BK4533","CHMP","IE00B894F039.SGD","BK4585","LU0234570918.USD","BIIB","LU0109394709.USD","BK4087","BK4588"],"gpt_icon":0},{"id":"2584642687","title":"High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2584642687","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584642687?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:00","pubTimestamp":1763377200,"startTime":"0","endTime":"0","summary":"Positive CHMP opinion is based on data from the DEVOTE study which evaluated the high dose regimen of nusinersen in treatment-naive participants and those transitioning from the currently approved 12m","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/17/3188941/0/en/High-Dose-Regimen-of-Nusinersen-Receives-Positive-CHMP-Opinion-for-the-Treatment-of-Spinal-Muscular-Atrophy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2308191902.HKD","LU1721427968.SGD","BK4217","LU1169589451.USD","LU2229751404.USD","LU2125910179.SGD","IE00BN0W2W23.USD","LU1620156213.USD","BK4081","WMS","SMA","LU1543694498.USD","LU2413665964.HKD","LU1169590202.USD","LU2089279066.USD","LU2413666004.HKD","LU0054578231.USD","LU1165135440.EUR","LU0012050646.USD","LU1596574779.USD","LU0106261612.USD","LU2125910336.SGD","IE00BN0W2V16.EUR","CHMP","LU0728928796.USD","BK4087","LU0757428866.USD","EMA","LU1815336091.USD","LU1923621640.USD","IE00BN0W2T93.GBP","LU1620156130.USD","BK4086"],"gpt_icon":0},{"id":"2584642833","title":"Incyte announces CHMP opinion recommending approval of Minjuvi combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2584642833","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584642833?lang=en_us&edition=fundamental","pubTime":"2025-11-17 18:45","pubTimestamp":1763376314,"startTime":"0","endTime":"0","summary":"Incyte (INCY) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued an opinion recommending...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/incyte-announces-chmp-opinion-recommending-approval-of-minjuvi-combination-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/incyte-announces-chmp-opinion-recommending-approval-of-minjuvi-combination-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INCY","BK4550","BK4532","BK4087","BK4585","BK4139","CHMP","BK4588"],"gpt_icon":0},{"id":"2583682450","title":"Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583682450","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583682450?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:05","pubTimestamp":1763154300,"startTime":"0","endTime":"0","summary":"– Company reports $14.3 million in revenue in Q3’25, consisting of $3.6 million in YCANTH revenue and $10.7 million of license and collaboration revenue – – Reports positive feedback from the FDA and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/14/3188609/0/en/Verrica-Pharmaceuticals-Reports-Third-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCC","BK4081","CHMP","BK4080","BK4104","BK4231","BK4567","EMA","BK4087","SITC"],"gpt_icon":0},{"id":"2583506963","title":"Anavex Faces CHMP Setback for Alzheimer’s Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2583506963","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583506963?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:58","pubTimestamp":1763125081,"startTime":"0","endTime":"0","summary":"Anavex Life Sciences ( ($AVXL) ) has issued an update. On November 14, 2025, Anavex Life Sciences announced that the Committee for Medicinal Produc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/anavex-faces-chmp-setback-for-alzheimers-drug?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/anavex-faces-chmp-setback-for-alzheimers-drug?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CHMP","BK4087"],"gpt_icon":0},{"id":"2583506953","title":"Ionis Pharmaceuticals announces CHMP opinion recommending Dawnzera approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2583506953","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583506953?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:46","pubTimestamp":1763124391,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals (IONS) and Otsuka Pharmaceutical announced that the Committee for Medicinal Products for Human Use of the European Medicines ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ionis-pharmaceuticals-announces-chmp-opinion-recommending-dawnzera-approval-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ionis-pharmaceuticals-announces-chmp-opinion-recommending-dawnzera-approval-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IONS","BK4139","CHMP","BK4087"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":49,"code":"91000000","status":"200"}]}}